Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Sinopharm, officially known as China National Pharmaceutical Group Co., Ltd., is a leading state-owned healthcare enterprise and the largest pharmaceutical company in China. The group operates across the entire industry value chain, encompassing research and development, manufacturing, logistics, and retail of pharmaceutical and healthcare products. It gained significant global recognition for its development of inactivated COVID-19 vaccines through its subsidiary, China National Biotec Group (CNBG). Beyond vaccines, Sinopharm is a major provider of small molecule drugs, biologics, and medical devices, serving both domestic and international markets. The company manages several publicly traded subsidiaries and maintains a vast distribution network that forms the backbone of China's medicine supply chain.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on China National Biopharmaceutical Group.